"Nanotechnology-Based Immunotherapy Promoting Transplant Acceptance"
Mount Sinai researchers have developed a novel type of immunotherapy based on innovative nanotechnology that induces long-term organ transplant acceptance in mice. Their study, published in Immunity, could transform patient care and help to overcome barriers that prevent successful long-term transplant outcomes. "Our findings and the development of a novel nano-immunotherapy platform represent a revolutionary approach to prevent organ transplant rejection," said co-lead investigator Jordi Ochando, PhD, assistant professor of medicine, oncological sciences, pathology and immunology at the Icahn School of Medicine at Mount Sinai. "Instead of suppressing the effects of organ transplantation (activated T-cells), we are preventing the cause (myeloid cell activation) in a highly specific yet short-term fashion. It's a completely different approach that can be employed to other conditions that are characterized by maladaptive trained immunity, such as autoimmune and cardiovascular diseases," said co-lead investigator Willem J.M. Mulder, PhD, professor of radiology and oncological sciences at the Icahn School of Medicine at Mount Sinai.
— Jordi Ochando, PhD, Assistant Professor, Medicine, Oncological Sciences, Pathology, Immunology, Icahn School of Medicine at Mount Sinai
— Willem J.M. Mulder, PhD, Professor, Radiology, Oncological Sciences, Icahn School of Medicine at Mount Sinai, Director, Nanomedicine Program at TMII
— Zahi Fayad, PhD, Director, TMII, Professor, Medical Imaging and Bioengineering, Radiology, Medicine, Cardiology, Icahn School of Medicine at Mount Sinai
Additional coverage: